TD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at WedbushAugust 4, 2025 1:24 PM Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at GuggenheimAugust 4, 2025 12:58 PM Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6cAugust 4, 2025 9:05 AM Form 8-K Praxis Precision Medicin For: Aug 04August 4, 2025 8:52 AM Form 10-Q Praxis Precision Medicin For: Jun 30August 4, 2025 8:34 AM Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 4, 2025 8:30 AM Praxis reports positive seizure reduction results from vormatrigine trialAugust 4, 2025 8:10 AM Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of VormatrigineAugust 4, 2025 8:00 AM